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Abstract
The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered 
an international pandemic that has led to significant public health problems. To date, limited evidence exists to suggest that drugs 
are effective against the disease. As possible treatments are being investigated, herbal medicines have shown potential for producing 
novel antiviral agents for the COVID-19 disease. 
Aim 
This review explored the potential of  Malawi’s traditional medicinal plants for the management of  COVID-19. 
Methods
The authors searched on PubMed and Google scholar for medicinal plants that are used in Malawi and published in openly available 
peer reviewed journals. Plants linked with antiviral treatment, anti-COVID-19 activity or COVID-19 symptoms management were 
targeted. These included activity against pneumonia, inflammation, cough, difficulty in breathing, pain/aches, fever, diarrhoea, 
rheumatism, fatigue, asthma, immunocompromised and  cardiovascular diseases.
Results
11 studies were found with 306 plant species. 127 plant species had at least one COVID-19 related pharmacological activity. Of  these 
plant species, the number of  herbal entities used for each indication was:   pain/aches (87), fever (2), pneumonia (9), breathing/asthma 
problems (5), coughing (11), diarrhoea (1), immunosuppression (8), blood issues (10), fatigue (2), heart problems (11), inflammation 
(8), rheumatism (10) and viral diseases (12). Thirty (30) species were used for more than one disease and Azedarachta indica topped 
the list (6 of  the 13 COVID-19 related diseases). The majority of  the species had phytochemicals known to have antiviral activity or 
mechanisms of  actions linked to COVID-19 and consequent diseases’ treatment pathways.
Conclusion
Medicinal plants are a promising source of  compounds that can be used for drug development of  COVID-19 related diseases. This 
review highlights potential targets for the World Health Organization and other research entities to explore in order to assist in 
controlling the pandemic. 
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Introduction
Viruses are pathogens that cause communicable diseases 
like flu, AIDS and Ebola and increasing evidence shows that 
some viruses play a role in the disease mechanism of  some 
non-communicable diseases like cancers, Alzheimer’s disease 
and type 1 diabetes with high morbidity and mortality rates 
worldwide.1 Most of  these diseases have proved hard to 
cure.2-5 Viruses cause epidemics that emerge and re-emerge 
and are easily transmitted to different locations due to 
increased global travel and rapid urbanization. Emergence of  
novel viruses and rapid mutation of  old viruses make drug as 
well as vaccine development challenging and these are some 
of  the major reasons why there has not been significant 
development of  effective drugs or vaccines against many 
viruses. Notable viruses that have caused outbreaks with 
significant public health implications worldwide include 
dengue virus, influenza virus, measles virus, severe acute 
respiratory syndrome (SARS) virus, and West Nile virus and 
the recently discovered severe acute respiratory syndrome 
corona virus 2 (SARS-CoV-2).6-9 The SARS-CoV-2 is a novel 
virus that was discovered in 2019 in Wuhan City of  Hubei 
Province in China and has spread rapidly throughout the 
world, causing serious health care burden. The virus causes a 
disease called COVID-19 disease that affects all populations 
of  people, but the elderly and those with underlying medical 
conditions are at a higher risk of  morbidity and mortality.10 
Being a novel disease caused by a novel virus, knowledge 
about the virus and the disease is limited and keeps on 
developing daily.11
SARS-CoV-2 is a 60 nm to 140 nm diameter, 
enveloped, positive sense RNA virus (11) belonging 
to the Coronaviruses (CoVs) that are generally 
enveloped viruses with single-stranded RNA genome. CoVs 
have the largest genomes to date among RNA viruses 
that range from approximately 26 to 32 kilobases. 
They replicate by genes encoding for 
viral structural proteins such as nucleocapsids (N), 
membranes (M), spikes (S), and envelopes (E), which play 
significant roles in viral integrity.12 However, there are other 
commonly studied proteins that have been widely targeted 
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for drug development. These include papain-like protease 
(PLpro), 3c-like protease (3CLpro) and spike protein13-16.  
Coronaviruses infections are well known for causing 
enteric, respiratory and central nervous system diseases in 
animals and humans.17 The nomenclature of  coronaviruses 
originates from spike-like projections on its surface, which 
gives it a shape similar to a crown when viewed under an 
electron microscope.16,18 The gene sequence of  SARS-CoV-2, 
the coronavirus responsible for COVID-19, suggests that 
its proteins are similar to those of  South Asia Respiratory 
Syndrome (SARS) or Middle East Respiratory Syndrome 
(MERS).19,20 Hence, drugs, compounds and medicinal 
plants or extracts known to inhibit these proteins in SARS 
and MERS could be promising leads for COVID-19 drug 
development.
COVID-19 is transmitted by large water droplets released by 
infected people (symptomatic or asymptomatic) when they 
cough and sneeze, and they survive in these droplets that 
are spread on the surfaces or individual’s bodies.21 Higher 
viral loads can be found in the nasal cavity than the throat.22 
People are infected by touching their nose, eyes or mouth 
after touching surfaces contaminated with SARS-CoV-2.23,24 
The virus enters the respiratory mucosa using angiotensin 
converting enzyme receptor 2 (ACE-2).25 The virus can easily 
be killed by common disinfectants such as ethanol (preferably 
≥ 80%), sodium hypochlorite or hydrogen peroxide.23,24
COVID-19 patients can be symptomatic, pre-symptomatic, 
or asymptomatic.26 Common clinical features are fever, dry 
cough, sore throat, fatigue, headache, conjunctivitis, myalgia 
and breathlessness as well as loss of  taste or smell.27-29 Some 
patients also develop pneumonia and respiratory failure and 
may die within weeks. The latter scenario is associated with an 
extreme increase in inflammatory cytokines (cytokine storm), 
especially IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and 
TNFα.30 The COVID-19 disease is also associated with 
complications such as acute lung injury, Acute Respiratory 
Distress Syndrome (ARDS), shock, and acute kidney injury.
Currently, there are no approved treatment medicines in use 
for COVID-19 disease. The disease is being managed by 
prevention of  transmission (face masks and washing hands 
with soap and water or using hand sanitizer), maintaining 
hydration and nutrition, controlling fever and cough, 
provision of  oxygen and renal replacement therapy. The use 
of  these interventions varies by availability, access, location 
and disease severity. Therefore, there is a need to discover, 
design or develop novel efficacious and cost-effective 
antivirals as the search for effective vaccines continues.9
Several approaches are being implemented to tackle 
COVID-19, one of  which is the repurposing of  widely 
used conventional and herbal medicines.31 Antiviral drugs 
(ribavirin, lopinavir-ritonavir based on experience in SARS 
and MERS), combination therapy of  oseltamivir, ganciclovir 
and lopinavir-ritonavir, and remdesivir (broad spectrum anti-
RNA drug developed for Ebola) have been tested. Remdesivir, 
the only antiviral option showing benefit to date, has shown 
statistically significant improvements in time to recovery in 
hospitalized patients in comparison with placebo.32 Short 
term therapy with low-to-moderate dose corticosteroids 
(such as dexamethasone) in COVID-19 ARDS, intravenous 
immunoglobulin therapy, arbidol (antiviral drug), interferons, 
hydroxychloroquine and plasma of  patients recovered from 
COVID-19 have been trialled. Despite preliminary reports 
showing that dexamethasone may decrease mortality rates 
among critically ill patients, more evidence about its efficacy 
and safety, along with other agents, are needed before these 
treatment options are fully recommended for use.30,33-39
Traditional medicines, especially Chinese herbs, have been 
tested for use in COVID-19.33 Aanouz et al., (2020) used 
computational techniques to evaluate the inhibition potential 
of  compounds isolated from plants used in Morocco against 
COVID-19 virus.  Sixty seven (67) compounds isolated from 
aromatic and medicinal plants were found and selected for 
molecular docking studies that used energy of  interaction 
between the compound’s functional groups and the corona 
virus (SARS-COV-2 spike protein) as one of  the criteria 
for anti-corona virus effect. Chloroquine was used as a 
standard (interaction energy of  -6 kcal/mol).  Eleven (11) 
molecules showed a good interaction with the target, but 
the three greatest activities were for Crocin from Crocus 
sativus L. (-8.2kcal/mol), Digitoxigenin (Nerium oleander L., 
-7.2 kcal/mol) and β -Eudesmol (Laurus nobilis L., -7.1kcal/
mol). Experimental data also showed that they had antiviral 
activity.40 For example, Crocin was found in vitro to be an 
inhibitor of  the replication of  Herpes Simplex Virus (HSV) 
before and after virion entry in Vero cells, and its plant/
herbal medicine source showed promise for use as an anti-
HSV and anti-Human Immunodeficiency Virus (HIV) 
agent.41 Derivatives of  Digitoxigenin are used as antiviral 
and anticancer inhibitors, while β–Eudesmol has substantial 
antibacterial and antiviral activity.42-43
Zhang et al., (2020) executed a rational computer-based 
screening study aimed at identifying Chinese medical herbs 
and compounds with antiviral activity against respiratory 
infections and COVID-19.  This computer-based study 
searched through literature for natural compounds and 
their respective traditional Chinese medicinal plants known 
to fight against MERS or SARS coronavirus.  Docking 
studies were completed to analyse their potential for direct 
interaction with SARS-COV-2 protein, followed by biological 
activity search from literature. Thirteen (13) out of  the 115 
compounds found in the search of  traditional Chinese 
medicines exhibited potential for anti-COVID-19 activity 
and 125  screened Chinese herbs contained 2 or more of  
the 13 compounds. A search for pharmacological activity 
showed that 26 of  the 125 herbs had antiviral activity in 
respiratory infection, and that they regulated viral infection, 
immune/inflammation reactions and response to hypoxia.44
Hui et al., (2020) evaluated studies that tested the use of  
Chinese medicine (CM) as prophylaxis on people exposed 
to SARS and H1N1 influenza in clinical trials, cohort or 
other population studies. Results showed that the Chinese 
medicines performed well as prophylaxis, an effectiveness 
that has also been recorded in historical practice with CM.45 
During the COVID-19 epidemic, several CM products were 
also tested in humans for prevention of  the epidemic effects 
and selection of  the CM was based on historical use and 
previous experimental results in similar viral epidemics. The 
CM used in the studies included radix astragali (Astragalus 
propinquus Schischkin), radix glycyrrhizae (Glycyrrhiza uralensis 
Fisch. ex DC.), radix saposhnikoviae (Saposhnikovia divaricata 
(Turcz.) Schischk.), rhizoma atractylodis macrocephalae 
(Atractylodes macrocephala Koidz.), lonicerae japonicae flos 
(Lonicera japonica Thunb.) and fructus forsythia (Forsythia 
suspensa (Thunb.) Vahl.). This study revealed that historical 
use and previous use of  the CM in similar epidemics provided 
clues for selection of  CM use and efficacy in COVID-19.45,46 
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Plant extracts of  Lycoris radiata (L’Hér.) Herb., Artemisia annua 
L., Pyrrosia lingua (Thunb.) Farw. and Lindera aggregata (Sims.) 
Kosterm. were also evaluated and found to have anti–SARS 
activity after a screening exercise of  hundreds of  CMs.47
Apart from whole plant extracts, phytochemicals have 
been evaluated and shown potential for activity against 
COVID-19 disease, including Saikosaponins Types A, B2, 
C, and D (phytochemicals belonging to naturally occurring 
triterpene glycosides). For example, Saikosaponins from 
Bupleurum spp., Heteromorpha spp., Scrophularia scorodonia 
L. have showed antiviral activity against a human and bat 
corona virus HCoV-229E , that together with OC43, causes 
the common cold.34,47 
Furthermore, inhibitors of  SARS enzymes (nsP13 helicase 
and 3CL protease) have also been isolated from plants. For 
example, myricetin is a flavonoid polyphenolic compound 
that has anti-oxidant properties.48 Scutellarein, a flavone 
isolated from Scutellaria lateriflora L., has shown activity against 
SARS.35,49 Phenolic compounds isolated from Isatis tinctoria 
L., Torreya nucifera (L.) Siebold & Zucc. and a water extract 
of  Houttuynia cordata Thunb. have also exhibited antiviral 
mechanisms against SARS.50 These water extracts have been 
particularly known to inhibit viral 3CL protease as well as 
blocking viral RNA-dependent RNA-polymerase activity.51
Herbal-western medicine combination therapies of  
lopinavir/ritonavir (anti-HIV medicines), arbidol (broad-
spectrum antiviral) and CM Shufeng Jiedu capsule as well as 
lopinavir/ritonavir and CM Shufeng Jiedu capsule have also 
been tested clinically. Clinical observations for both herbal-
western medicine combination therapies treated patients 
showed that the TCMs treatments were effective in a majority 
of  the patients that were treated with them, which showed 
that the TCMs can play a role in treating COVID-19. The 
Herbal-western medicine combination therapies were very 
important in the treatment of  the viral pneumonia. It was 
found that more studies were needed to produce conclusive 
results on the curing capability of  the combination therapies 
on COVID-19.52
In the search for chemotherapy for COVID-19, there are 
different sources of  medicines, one of  which is traditional 
medicines or medicinal plants. In the African region including 
Malawi, treatment options commonly stem from medicinal 
plants due to their abundance and untapped potential. 80% 
of  the population in this region relies on medicinal plants as 
a primary health care option.53
Several studies have already started exploring plants for 
COVID-19 cure.32,54 There may be other unexplored plants 
that have potential for producing a cure for the disease 
or addressing mild to severe symptoms. Therefore, it is 
important to analyse the plants that have shown potential for 
COVID-19 activity and study plants with similar attributes. 
The following section explores the literature on studies that 
have evaluated the efficacy of  medicinal plants on SARS-
CoV-2 as well as searching for plants with similar antiviral 
potential in Malawi. For a plant or its isolated compounds 
to have potential for use in COVID-19, it should be able 
to kill or inactivate the virus or alleviate the symptoms and 
complications caused by coronavirus infection.
Significance of the Study on Medicinal plants with 
potential for use in COVID-19 in Malawi
The WHO recommends supportive care options such as 
the use of  supplemental oxygen through ventilators but 
these interventions are too expensive for most low-income 
countries with under resourced healthcare systems.55,56 
Furthermore, there are gaps in trained health care providers 
for such interventions.57 The majority of  biomedical 
COVID-19 treatment options available lack data to support 
their effectiveness.55 Options that are showing some clinical 
promise have soaring prices and frequent stock outs.58 
Hence, medicinal plants may be alternatives for individuals 
in Malawi and other developing countries. Although there 
have been in-vitro studies that have shown activity for 
various aspects of  COVID-19, there hasn’t been a study 
completed in Malawi to assess the efficacy or toxicity of  
medicinal plants. Although various medicinal plants have 
been analysed abroad, these data cannot be extrapolated to 
the same species in Malawi since geographical differences 
have been identified in medicinal plants’ composition and 
activity.59 Hence, this study seeks to provide baseline data 
for use in the discussion of  Malawi’s medicinal plants use 
in COVID-19 treatment. Furthermore, it may confirm or 
refute widely-circulating arguments or fears concerning the 
use of  medicinal plants against COVID-19. This will be 
achieved by the following specific objectives: To examine 
published ethnobotanical studies conducted in Malawi in 
order to identify the medicinal plants with demonstrated 
activity or potential for activity against COVID-19 disease. 
To evaluate the literature for reported pharmacological 
properties of  medicinal plants found to have potential for 
use in COVID-19 disease.
Methods
The authors searched for studies on medicinal plants that 
are used in Malawi that met the following inclusion criteria: 
Published in peer reviewed journals that were openly 
available online between January 1994 and July 2020. Had 
medicinal plants reported to be found and used in Malawi 
by at least one ethnobotanical survey as well as being tested 
in a laboratory.
The plant had been linked with antiviral or anti-COVID-19 
use or against the symptoms of  COVID-19. The key words 
that were used on Google Scholar and PubMed were: 
Ethnobotany, ethnobotanical survey, Malawi, Malawi herbal 
medicine, Malawi herbalist, Malawi medicinal plant, Malawi 
phytochemical screening, Malawi herbals and traditional 
medicine.  Eleven (11) studies met the inclusion criteria while 
over 93 studies were excluded because plants reported were 
not cited in the ethnobotanical surveys reported in Malawi. 
All plant extracts that had potential for use in COVID-19 
were considered. That potential was shown by its local 
use on viral infections or antiviral activity (e.g., curative 
action against pneumonia and inflammation),   COVID-19 
symptoms (symptom management of  cough, difficulty in 
breathing, pain/aches, fever, diarrhoea, rheumatism and 
fatigue) and risk factors (high risk comorbidities like asthma, 
immunocompromise and cardiovascular diseases).
For the plants that met the above criteria, further searches were 
conducted on Google Scholar and PubMed using key words: 
scientific or botanical name of  the plant, phytochemicals, 
bioactivity and pharmacological activity to find out if  there 
have been any laboratory studies in Malawi or any other 
country to evaluate their biological or pharmacological 
activity on COVID-19 and consequent diseases.  Summaries 
of  all the studies and plants were created using Microsoft 
Excel.
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Results
The literature search found a total of  11 studies.60-70 Plant 
list extraction yielded 306 plant species thereafter removing 
species that were irrelevant or not identified by a botanist 
(Additional File 1: Table 1). Of  these 306 medicinal plants, 
127 plants were found to manage at least one of  the 
symptoms related to COVID-19 or were found to be used 
for the management of  viral infections (Additional File 2: 
Table 2). Table 3 shows a summary of  the results shown in 
the Additional File 2.
This study revealed that 87 of  127 medicinal plants could be 
used for pain or aches management, and two of  those for 
fever management (Azadirachta indica A. Juss. and Pyrenacantha 
kaurabassana Baill.). Pneumonia is another symptom associated 
with COVID-19. In this study, we found 9 medicinal plants 
that are used traditionally to manage pneumonia and 5 that 
have potential for use in managing breathing or asthma 
problems. Other diseases associated with COVID-19 for 
which we identified traditional medicines included coughing 
(11 plants), diarrhoea (1 plant), immunosuppression (8 
plants), blood related issues (10 plants), fatigue (2 plants), 
heart problems (11 plants), inflammation (8 plants) and 
rheumatism (10 plants). COVID-19 is a viral infection and 
any medicinal plant used for viral diseases has potential of  
being tested on coronavirus. There were 12 plants found to 
have been used for viral infections or diseases.
Of  the 127 medicinal plants with potential to manage 
COVID-19 related diseases or symptoms, 30 had more than 
one disease for which they could be used. Azedarachta indica 
topped the list with being used for 6 of  the 13 COVID-19 
related diseases, high risk comorbidities and symptoms 
followed by Moringa oleifera Lam. Pyrenacantha kaurabassana 
Baill. and Sclerocarya birrea (A. Rich.) Hochst. that could be 
used on 4 aspects of  COVID-19. Analysis of  these 30 plants 
revealed that they covered all types of  the diseases except 
one; fatigue. Table 4 shows the 30 plant species and their 
associated benefits for COVID-19 management. 
Pharmacological effects of the plants
The 30 plants with activity against one or more aspects of  
COVID-19 were considered more user-friendly since one 
entity can be used for multiple purposes. This may lead to a 
decreased incidence of  toxicity and interactions. However, it 
should also be pointed out that the use of  medicinal plants 
potentially leads to the administration of  multiple active 
compounds (drug promiscuity), and is dangerous as it risks 
drug resistance and adverse events from unknown drug-drug 
interactions. Some of  the components therein would be 
administered to the patient in suboptimal doses and others 
in overdoses, with chances of  drug resistance and toxicity.71
On the other hand, documented evidence exists that 
suggests that the use of  more than one medicinal plant 
(polyherbalism) improves the efficacy of  the products as 
well as convenience for patients during administration (dose 
and frequency). Research also suggests that combining 
medicinal plants with more than one pharmacological 
effect can provide even greater benefit.72 Therefore, the 30 
plants with multiple COVID-19 activities were evaluated 
further using literature review to determine if  any studies 
had been completed to scientifically confirm their traditional 
ethnobotanical uses. Table 5 shows a summary of  studies 
done so far on the plants. The table shows that the majority 
of  the medicinal plants had phytochemicals linked to several 
of  their COVID-19 symptoms alleviation capabilities and 
had demonstrated some mechanism of  action related to 
COVID-19 treatment pathways. A few medicinal plants had 
no studies conducted to confirm their use.
Discussion
This study has demonstrated that there are multiple 
medicinal plants in Malawi that are being used for disease 
state management (Additional File 1: Table 1) and that several 
of  these diseases are symptoms associated with COVID-19 
(Additional File 2: Table 2). According to the World Health 
Organization (WHO), patients with mild COVID-19 are 
recommended to be treated with medicines that manage the 
presenting symptoms.55 
The WHO acknowledges that traditional medicines may be 
sources of  new therapies in the search for potential treatments 
for COVID-19. This is based on the historical integration of  
medicinal plants into primary healthcare in many areas of  the 
world and on phytochemicals serving as precursor molecules 
for several commonly used biomedical drugs.55 This study 
was completed as a way of  supplementing in the search for 
therapies for COVID-19 since initial selection of  potential 
plant species for plant-derived lead compounds or medicines 
stems from ethnobotanical surveys. Since the disease is 
novel, we could not identify a novel medicinal entity with 
clinically significant SARS-COV-2 activity. However, plants 
targeting other viruses and associated symptoms might be 
repurposed in a similar fashion to various conventional 
medicines.73 However, the WHO warns against the use 
of  traditional medicines without evaluating them first for 
efficacy, toxicity, and safety. Although WHO recognizes 
that traditional, complementary and alternative medicines 
show beneficial effects, and that Africa has a long history of  
traditional medicine use, medicinal plants can also be toxic 
and medicinal plants’ efficacy may vary due to differences in 
geographical locations.55,59,73
The majority of  the 30 medicinal plants identified contained 
known phytochemicals (Table 4 and 5). The review of  the 
pharmacological effects of  the plants confirms why they 
have potential for testing in the management of  COVID-19 
patient symptoms and eliminating the virus. The results, for 
example on Azadrachta indica, are consistent with the results 
reported by Roy and Bhattacharyya (2020), Shanmuga 
(2020), as well as Shanmuga et al., (2020) that also showed 
the potential of  this plant in review, computational work, 
and clinical case study respectively.74-76 Furthermore, the 
study results are similar to those of  Li et al who describe 
the Shufeng Jiedu Capsule/Granule (SFJD) containing eight 
medicinal herbs in China that is reported to have antiviral, 
antibacterial, antitumor, and anti-inflammatory activities, and 
have effective protection against lung injury and neuronal loss 
achieved through enhancement of  autophagy and apoptosis 
reduction in rats with allergic rhinitis.77 It is also reported 
to improve Pseudomonas aeruginosa-induced upper respiratory 
tract infection by acting on various targets, particularly 
ERK phosphorylation. When combined with oseltamivir 
treatment, SFJD reduced IAV-induced airway inflammation 
and pulmonary virus titres. This suggests that SFJD may be 
used for the prevention and treatment of  infectious diseases 
by regulating various signal pathways.77
This study can assist WHO’s efforts to select traditional 
medicine products that can be investigated for clinical 
efficacy and safety in COVID-19. The WHO has historically 
supported clinical trials of  traditional medicine products. 
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29. Dell’Era V, Farri F, Garzaro G, Gatto M, Valletti PA, Garzaro M. 
Smell and taste disorders during COVID‐19 outbreak: A cross‐sectional 
Through these previous WHO trials, 89 products have been 
given market authorisation in 14 countries after meeting 
international and national requirements for registration. 
Furthermore, 43 products were included in national essential 
medicines lists for diseases including malaria, opportunistic 
infections related to HIV, diabetes, sickle cell disease and 
hypertension.55 This report recommends that the medicinal 
plants identified be evaluated as potential sources of  
COVID-19 management remedies and be prioritized for 
inclusion in clinical and analytical studies for antiviral activity 
or management of  COVID-19 disease.
Conclusions
Coronaviruses have been in existence for decades and novel 
strains will continue to emerge. Efforts to find viable, safe and 
effective treatments in drug discovery pipelines are continuing 
and will adapt in response to evolving strains. From various 
community practices across the world, natural products have 
played a significant role in managing coronavirus related 
diseases to varying extents. As the aetiology of  COVID-19 
disease is studied further at the molecular and enzyme levels, 
a narrower selection can be made for potential hits and leads 
effective against the disease. Natural products, including 
plant products, are undoubtedly a promising source of  
compounds in drug development for possible drug leads 
and vaccines. It is recommended that multidisciplinary 
approaches are used to study active phytochemicals with 
regard to identifying suitable compounds that can be used 
as they are or developed into possible treatments against 
Covid-19 and other related coronavirus diseases.
Acknowledgements
We thank Dr David Scott for assisting with the editing of  
the paper.
References
1. Parvez MK, Parveen S. Evolution and Emergence of Pathogenic 
Viruses: Past, Present, and Future.  Intervirology. 2017; 60 (1-2): 1-7.
2. Ball MJ, Lukiw WJ, Kammerman EM, Hill JM. Intracerebral 
propagation of Alzheimer’s disease: strengthening evidence of a herpes 
simplex virus etiology. Alzheimers Dem. 2013; 9 (2): 169-175.
3. Hober D, Sane F, Jaïdane H, Riedweg K, Goffard A, Desailloud 
R. Immunology in the clinic review series; focus on type 1 diabetes 
and viruses: role of antibodies enhancing the infection with 
Coxsackievirus-B in the pathogenesis of type 1 diabetes. Clin. Exp. 
Immuno. 2012; 168 (1):47-51.
4. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter 
Y. Eradication of hepatitis C virus infection and the development of 
hepatocellular carcinoma: a meta-analysis of observational studies. Ann 
Intern Med.  2013; 158: 329-337.
5. Herrington CS, Coates PJ, Duprex WP. Viruses and disease: emerging 
concepts for prevention, diagnosis and treatment. J Pathol.2015; 
235(2):149-152.
6. Christou L. The global burden of bacterial and viral zoonotic 
infections. Clin Microbiol Infect.2011; 17(3): 326-330.
7. Cascio A, Bosilkovski M, Rodriguez-Morales AJ, Pappas G. The 
socio-ecology of zoonotic infections. Clin. Microbiol. Infect. 2011; 
17(3): 336-342.
8. Grais RF, Strebel P, Mala P, Watson J, Nandy R, Gayer M. Measles 
vaccination in humanitarian emergencies: a review of recent practice. 
Confl. Health. 2011; 5(2):21.
9. Lin CC, Hsu LT, Lin WC. Antiviral natural products and herbal 
medicines. J. Trad. complement. 2014; 4(1): 24-35.
Malawi Medical Journal 33 (2); 85-107 June 2021 Medicinal plants in Covid-19 disease management  90
https://dx.doi.org/10.4314/mmj.v33i2.4
study on 355 patients. Head Neck. 2020; 42(7):  1591-1596.
30. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. et al. 
Epidemiological and clinical characteristics of 99 cases of 2019 novel 
coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet. 
2020; 395: 507-513.
31. Panyod S et al. Dietary therapy and herbal medicine for COVID-19 
prevention: A review and perspective. Journal of traditional and 
complementary medicine. 2020;  10(4): 420-427.
32. Beigel JH, Finberg RW, ACTT-1 Study Group Members. Remdesivir 
for the Treatment of Covid-19 - Preliminary Report. COVID-19 
Publications by UMMS Authors. 2020.
33. Jin YH, Cai L, Cheng ZS. et al. A rapid advice guideline for the 
diagnosis and treatment of 2019 novel coronavirus [2019-nCoV] 
infected pneumonia [standard version].Mil Med Res. 2020; 7(4)..
34. Zhang L, Liu YJ. Potential interventions for novel coronavirus in 
China: A systematic review. Med. Virol. 2020; 92(5): 479-490.
35. Expert consensus on chloroquine phosphate for the treatment 
of novel coronavirus pneumonia. Multicenter collaboration group, 
Department of Science and Technology of Guangdong Province and 
Health Commission of Guangdong Province, Chloroquine in the 
treatment of novel corona. Zhonghua Jie He He Hu Xi Za Zhi.2020; 
43 (0):E019.
36. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce 
H. et al. First Case of 2019 Novel Coronavirus in the United States., 
Washington State 2019-nCoV Case Investigation Team. Engl. J. 
Med.2020; 382(10): 929-936.
37. Russell CD, Millar JE, Baillie JK. Clinical evidence does not 
support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 
2020; 395: 473-475.
38. Zhao JP, Hu Y, Du RH. et al. Expert consensus on the use of 
corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie 
He He Hu Xi Za Zhi. 2020; 43: E007.
39. Covid-19: Demand for dexamethasone surges as RECOVERY trial 
publishes preprint. . BMJ. 2020; 369.
40. Aanouz I, Belhassan A, Khatabi KE, Lakhlifi T, Idrissi ME. 
Bouachrine M. Moroccan Medicinal plants as inhibitors of COVID-19: 
Computational investigations.J. Biomolec. Structure and Dynam. 
2020: 1-9.
41. Soleymani S, Zabihollahi R, Shahbazi S, Bolhassani A. Antiviral 
effects of saffron and its major ingredients. Curr. Drug Deliv. 2018; 
15(5): 698-704.
42. Boff L et al. Potential anti-herpes and cytotoxic action of novel 
semisynthetic digitoxigenin-derivatives. Eur. J. Med. Chem. 2019; 167: 
546-561.
43. Astani A, Reichling J, Schnitzler P. Screening for antiviral activities 
of isolated compounds from essential oils. Evid. Based Complement. 
Alternat. Med. 2011; , 2011.
44. Zhang XR, Kaunda JS, Zhu HT, Wang D, Yang CR, Zhang YJ. 
The Genus Terminalia (Combretaceae): An Ethnopharmacological, 
Phytochemical and Pharmacological Review. Nat. Prod. 
Bioprospect.2019; 9: 357-392.
45. Luo H, Tang Q, Shang Y et al.  Can Chinese Medicine Be Used 
for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review 
of Historical Classics, Research Evidence and Current Prevention 
Programs. Chinese J. Integ. Med. 2020; 26: 243-250.
46. Xiong X, Wang P, Su K, Cho WC, Xing Y. Chinese herbal medicine 
for coronavirus disease 2019: A systematic review and meta-analysis. 
Pharmacological research. 2020; 160(105056).
47. Li SY, Chen C, Zhang HQ, Guo HY, Wang H, Wang L. et al. 
Identification of natural compounds with antiviral activities against 
SARS-associated coronavirus. Antiviral research. 2005; 67(1): 18-23.
48. Yu MS, Lee J, Lee JM, et al. Identification of myricetin and 
scutellarein as novel chemical inhibitors of the SARS coronavirus 
helicase, nsP13. Bioorg Med Chem Lett. 2012; 22(12): 4049-4054.
49. Mani JS, Johnson JB, Steel JC, et al. Natural product-derived 
phytochemicals as potential agents against coronaviruses: A review. 
Virus Res. 2020; 284: 197989. doi:10.1016/j.virusres.2020.197989, 
Vol. 284.
50. Ryu YB., Jeong HJ, Kim JH, Kim YM, Park JY, Kim D. et al. 
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL (pro) 
inhibition.Bioorg. Med. Chem. 2010; 18(22):  7940-7947.
51. Lau KM, Lee KM, Koon CM, Cheung CS, Lau CP, Ho HM. et al. 
Immunomodulatory and anti-SARS activities of Houttuynia cordata. J. 
ethnopharm. 2008; 118(1): 79-85.
52. Wang Z, Chen X , Lu Y, Chen F, Zhang W. Clinical characteristics 
and therapeutic procedure for four cases with 2019 novel coronavirus 
pneumonia receiving combined Chinese and Western medicine 
treatment. BioSci. Trends.2020; 14(1): 64-68.
53. Oyebode O, Kandala NB, Chilton PJ, Lilford RJ. Use of traditional 
medicine in middle-income countries: a WHO-SAGE study. Health 
Policy Plan.2016; 31(8): 984-991.
54. Zhang D, Wu K, Zhang X, Deng S, Peng B. In silico screening 
of Chinese herbal medicines with the potential to directly inhibit 2019 
novel coronavirus. J. Integ. Med. 2020; 18(1):152-158.
55. World Health Organisation (WHO). WHO supports scientifically-
proven traditional medicine. 2020. www.afro.who.int/news/who-supp. 
Accessed on 25/07/2020.
56.Loayza NV. Costs and Trade-Offs in the fight against the COVID-19 
Pandemic: A Developing Country Perspective (English). Research and 
Policy Briefs. Washington DC : World Bank Group, 2020.
57. Gadabu A. Malawi’s Response, Risk Factors, and Preparedness for 
COVID-19. North American Academic Research –NAAR. 20203(4): 
http://doi.org/10.5281/zenodo.3732795.
58. Rajagopal D. Hydroxychloroquine becomes a Schedule H1 drug 




59. Nafiu MO, Hamid AA, Muritala HF Adeyemi SB. Chapter 7 - 
Preparation, Standardization, and Quality Control of Medicinal Plants 
in Africa. 2017. in: Medicinal Spices and Vegetables from Africa. 2017: 
171-204.
60. Chikowe I, Mnyenyembe M, Jere S, Mtewa AG , Mponda J, Lampiao 
F. An ethnomedicinal survey of indigenous knowledge on medicinal 
plants in the traditional authority Chikowi in Zomba, Malawi. Current 
Traditional Medicine.2020; 5(1)..
61. Mwafongo E, Nordal I, Magombo Z, Stedje B. Ethnobotanical 
study of Hyacinthaceae and non-hyacinthaceous geophytes in selected 
districts of Malawi. . Ethnobot. Res. Appl. 2010; 8: 75-93.
62. Robinson L, Sclar D, Scaer T. Medicinal Plant Use by Traditional 
Healers in Malawi: Focus on Neem, Tephrosia, Moringa, Jatropha, 
Marula and Natal Mahogany. Malawi Agroforestry Extension Project. 
2002: 11-18.
63. Saka JD, Msonthi JD. Nutritional value of edible fruits of indigenous 
wild trees in Malawi.For. Ecol. Manage.1994; 64: 245-248.
64. Manda L. Status and uses of Oldfieldia dactylophylla (Euphorbiaceae) 
in Malawi. Uppsala : CBM Master Theses No. 38. Swedish Biodiversity 
Centre (CBM), SLU, Box 7007, SE-750 07. 2007; Uppsala, Sweden.
65. Maliwichi-Nyirenda CP, Maliwichi LL. Medicinal plants used for 
contraception and pregnancy-related cases in Malawi: A case study 
of Mulanje District.Journal of Medicinal Plants Research. 2010; 
4(20):3024-3030.
66. Gordon CN. People and protected areas: Natural resource 
Malawi Medical Journal 33 (2); 85-107 June 2021 Medicinal plants in Covid-19 disease management  91
https://dx.doi.org/10.4314/mmj.v33i2.4
harvesting as an approach to support rural communities surrounding 
Majete Wildlife Reserve, Southern Malawi. Capetown : Masters thesis. 
Stellenbosch University, South Africa. 2017.
67. Bundschuh TV, Hahn K, Wittig R. The Medicinal Plants of the 
Woodlands in northern Malawi (Karonga District). Flora et Vegetatio 
Sudano-Sambesica.2011; 14:  3-8.
68.Maliwichi-Nyirenda CP. The conservation biology of Berberis 
holstii engl. in Nyika national park, Malawi. Plymouth : University of 
Plymouth Research Theses. 2008.
69. Kayambazinthu D, Barany M, Mumba R, Anyonge CH. Miombo 
woodlands and HIV/AIDS interactions: Malawi Country Report. Food 
and Agriculture Organization of the United Nations. Forestry Policy 
and Institutions Working Paper 6. Rome : FAO, 2005.
70.Chisaka JW. The use of traditional herbal medicines among palliative 
care patients at Mulanje Mission Hospital, Malawi. Capetown : Faculty 
of Health Sciences, Department of Public Health and Family Medicine, 
University of Capetown.2019. .
71. Mei Y, Yang B. Rational application of drug promiscuity in 
medicinal chemistry. Future medicinal chemistry. 2018; 10(15).
72. Parasuraman S, Thing GS, Dhanaraj SA. Polyherbal formulation: 
Concept of ayurveda. Pharmacogn. Rev. 2014; 8(16): 73-80.
73. Yang Y. Use of herbal drugs to treat COVID-19 should be with 
caution. The Lancet. 2020; 395(10238): 395.
74. Roy S, Bhattacharyya P. Possible role of traditional medicinal plant 
Neem (Azadirachta indica) for the management of COVID-19 infection. 
International Journal of Research in Pharmaceutical Sciences..2020; 
11(SPL1): 122-125.
75. Shanmuga SS. Some Compounds from Neem leaves extract exhibit 
binding affirnity as high as -14.3 kcal/mol against COVID-19 Main 
Protease (Mpro): A Molecular Docking Study. Molecular Biology.2020. 
DOI: 10.21203/rs.3.rs.2564/v1. 
76. Shanmuga SS, Kanitkar PM, Neeta, Shirish K. Neem (Azadirachta 
Indica) leaves in the treatment of COVID19/SARS-CoV-2 : A Case 
Report. Figshare. 2020; Figshare. Preprint.
77. Li C, Wang L, Ren L. Antiviral mechanisms of candidate chemical 
medicines and traditional Chinese medicines for SARS-CoV-2 infection 
[published online ahead of print, 2020 Jun 24].Virus Res.2020; 
286(198073).
78. Ramadass N, Subramanian N. Study of phytochemical screening 
of neem (Azadirachta indica). Int. J. Zoo. Studies.2018; 3(1): 209-212.
79. Dash SP, Dixit S, Sahoo S. Phytochemical and Biochemical 
Characterizations from Leaf Extracts from Azadirachta Indica: An 
Important Medicinal Plant. Biochem. Anal. Biochem.2017; 6(323).
80. Arora R, Chawla R, Marwah R, et al. Potential of Complementary 
and Alternative Medicine in Preventive Management of Novel H1N1 
Flu (Swine Flu) Pandemic: Thwarting Potential Disasters in the Bud. 
Evid Based Complement Alternat Med. 2011; 2011.
81. Bhowmik D, Chiranjib, Yadav J, Tripathi KK, Kumar KPS. Herbal 
Remedies of Azadirachta indica and its Medicinal Application. J. Chem. 
Pharm. Res. 2010; 2(1):  62-72.
82. Hannan A, Khan SA, Choudhry et al. Antibacterial activity of Neem 
(Azadirachta indica) leaf extracts against wound causing bacteria. 
Healthmed. 2014; 8(6): 767-773.
83. Lakshmi T, Krishnan V, Rajendran R, Madhusudhanan N. 
Azadirachta indica: A herbal panacea in dentistry - An update. 
Pharmacogn. Rev. 2015; 9(17): 41-44.
84. Alzohairy MA. Therapeutics Role of Azadirachta indica (Neem) 
and Their Active Constituents in Diseases Prevention and Treatment. 
Evid Based Complement. Alternat. Med.2016; 2016.
85. Connelly MP, Fabiano E, Patel IH, Kinyanjui SM, Mberu EK, 
Watkins WM. Antimalarial activity in crude extracts of Malawian 
medicinal plants. Ann Trop Med Parasitol. 1996; 90(6):  597-602.
86. Maroyi A. Azanza garckeana Fruit Tree: Phytochemistry, 
Pharmacology, Nutritional and Primary Healthcare Applications as 
Herbal Medicine: A Review. Res. J. Med. Plants. 2017; 11: 115-123.
87. Yusuf AA, Lawal B, Sani S. et al. Pharmacological activities of 
Azanza garckeana (Goron Tula) grown in Nigeria. Clin. Phytosci. 2020; 
6: 27.
88. Srivastava S, Srivastava M, Misra A, Pandey G, Rawat A. A review 
on biological and chemical diversity in Berberis (Berberidaceae). 
EXCLI J. 2015; 14: 247-267.
89. Kimani NL, Njangiru IK, Njagi ENM, Orinda GO. Antidiabetic 
activity of administration of aqueous extract of Berberis holstii. 11, 
2017, J. Diabetes Metab., Vol. 8.
90. Pathy K. The Influenza a Virus Subtypes H1N1, H1N2 and H3N2, 
HDFx: A Novel Immunomodulator and Potential Fighter Against 
Cytokine Storms in Viral Flu Infections- Carica Papaya Linn. Int. J. 
clin. Case. 2017; 1(8): 159-165.
91. Saeed F, Arshad MU, Pasha I, Naz R, Batool R, Khan AA, et al. 
Nutritional and Phyto-Therapeutic Potential of Papaya (Carica Papaya 
Linn.): An Overview. International Journal of Food Properties.2014; 
17(7): 1637-1653.
92. Ahmad N, Fazal H, Ayaz M, Abbasi BH, Mohammad I, Fazal L. 
Dengue fever treatment with Carica papaya leaves extracts. Asian Pac. 
J. Trop. Biomed. 2011; 1(4): 330-333.
93. Srikanth BK, Reddy L, Biradar S, Shamanna M, Mariguddi DD, 
Krishnakumar M. An open-label, randomized prospective study to 
evaluate the efficacy and safety of Carica papaya leaf extract for 
thrombocytopenia associated with dengue fever in pediatric subjects. 
Pediatric Health Med. Ther. 2019; 10: 5-11.
94. Priyadarshi A, Ram B. A review on pharmacognosy, phytochemistry 
and pharmacological activity of Carica papaya (linn) leaf. Int J Pharm 
Sci & Res.2018; 9(10): 4071-78.
95. Bhatnagar S, Sahoo S, Mohapatra AK, Behera DR. Phytochemical 
analysis, Antioxidant and Cytotoxic activity of medicinal plant 
Combretum roxburghii (Family: Combretaceae). Int. J. Drug Dev. & 
Res.2012; 4(1): 193-202.
96. de Morais LGR, de Sales IRP, Caldas FMRD, et al. Bioactivities 
of the genus Combretum (Combretaceae): A review. Molecules. 2012; 
17: 9142–206.
97. Makhafola TJ, Elgorashi EE, McGaw LJ, Awouafack MD, 
Verschaeve L, Eloff JN. Isolation and characterization of the compounds 
responsible for the antimutagenic activity of Combretum microphyllum 
(Combretaceae) leaf extracts. BMC Complement Altern Med. 2017; 
17(1): 446.
98. Maroyi A. Dicoma anomala sond: A review of its botany, 
ethnomedicine, phytochemistry and pharmacology. Asian J. 
Pharmaceut. Clin. Res. 2018; 11(6): 70.
99. Eramma N, Gayathri D. Antibacterial potential and phytochemical 
analysis of Flacourtia indica (Burm.f.) Merr. root extract against human 
pathogens. Indo American J. Pharmaceut. Res. 2013; 3: 3832-46. 
100. Adesina et al.Plants in Respiratory Disorders II- Antitussives, A 
Review.BJPR. 2017; 16(3): 1-21.
101. Sunday B, Atawodi E, Olowoniyi OD. Pharmacological and 
Therapeutic Activities of Kigelia africana (Lam.). Ann. Res. Rev. 
Bio.2015; 1: 1-17.
102. Singh L, Singh J, Singh J. Medicinal and Nutritional Values of 
Drumstick Tree (Moringa oleifera):A Review. Int.J.Curr.Microbiol.
App.Sci.2019; 8(05): 1965-1974.
103. Asnaashari S, Dastmalchi S, Javadzadeh Y. Gastroprotective 
effects of herbal medicines (roots). Int. J. Food Prop. 2018; 21(1):902-
920.
Malawi Medical Journal 33 (2); 85-107 June 2021 Medicinal plants in Covid-19 disease management  92
https://dx.doi.org/10.4314/mmj.v33i2.4
104. Oko AO, Ekigbo JC, Idenyi JN. Nutritional and Phytochemical 
Compositions of the Leaves of Mucuna Poggei. J. Bio. Life Sci. 2012; 
3(1):  232.
105. Vongtau H, Amos S, Hohn-Africa LB. Pharmacological effects 
of the aqueous extract of Neorautanenia mitis in rodents. Journal of 
Ethnopharmacology. 2000; 72(1-2): 207-14.
106. Dawurung CJ, Gotep JG, Usman JG, Elisha IL, Lombin LH, Pyne 
SG. Antidiarrheal activity of some selected Nigerian plants used in 
traditional medicine. Phcog. Res. [serial online]. 2019; 11:371-7.
107. Afolayan M, Srivedavyasasri R, Asekun OT, Familoni OB, 
Orishadipe A, Zulfiqar F. et al. Phytochemical study of Piliostigma 
thonningii, a medicinal plant grown in Nigeria. Med. Chem. Res.2018; 
27: 2325-2330.
108. Omolo JJ, Maharaj V, Naidoo D, Klimkait T, Malebo HM, Mtullu 
S, Lyaruu HM, de Koning CB. Bioassay-Guided Investigation of the 
Tanzanian Plant Pyrenacantha kaurabassana for Potential Anti-HIV-
Active Compounds. J. Nat. Prod. 2012; 75(10): 1712-1716.
109. Russo D, Kenny O, Smyth T, Milella L, Hossain M, Diop M, Rai 
D, Brunton N. Profiling of Phytochemicals in Tissues from Sclerocarya 
birrea by HPLC-MS and Their Link with Antioxidant Activity.ISRN 
Chromatography.  2013: 1-11.
110. John AO, Ojewole, Mawoza T, Witness DH, Chiwororo, Peter 
MO. Sclerocarya birrea (A. Rich) Hochst. [‘Marula’] (Anacardiaceae): 
A Review of its Phytochemistry, Pharmacology and Toxicology and its 
Ethnomedicinal Uses. Phytother. Res.2010; 24: 633-639.
111. Pallant CA, Cromarty AD, Steenkamp V.  Effect of an alkaloidal 
fraction of Tabernaemontana elegans (Stapf.) on selected micro-
organisms.J Ethnopharmacol.2012; 140(2): 398-404.
112. Hapsari BW, Martin AF, Maulana E, Ermayanti TM. Growth, 
phytochemical properties, and antioxidant activity of in vitro-gamma 
irradiated Tacca leontopetaloides (L.) Kuntze. AIP Conference 
Proceedings. 2019; 2199.
113. Mkindi AG, Tembo Y, Mbega ER, et al. Phytochemical Analysis 
of Tephrosia vogelii across East Africa Reveals Three Chemotypes that 
Influence Its Use as a Pesticidal Plant.Plants (Basel). 2019; 8(12): 597.
114. Yadeta NC, Tessema SS. Phytochemical Investigation and 
characterisation of the chemical cosntituents from root extracts 
of Tephrosia vogelli. International Journal of Novel Research in 
Engineering and Science. 2019; 6(2):  1-14.
115. Mongaloa NI, McGawa LJ, Segapelod TV, Finniea JF, Van Staden 
VJ. Ethnobotany, phytochemistry, toxicology and pharmacological 
properties of Terminalia sericea Burch. ex DC. (Combretaceae) – A 
review. J. Ethnopharm. 2016; 194: 789-802.
116. Viol DI. Screening of traditional medicinal plants from 
Zimbabwe for phytochemistry, antioxidant, antimicrobial, antiviral 
and toxicological activities. School of Pharmacy, College of Health 
Sciences, University of Zimbabwe Thesis. 2009.
117.Cock IE.The medicinal properties and phytochemistry of plants 
of the genus Terminalia (Combretaceae). Inflammopharmacol.2015; 
23(5): 203-29. 
118. Konate K, Yomalan K, Sytar O, Brestic M. Antidiarrheal and 
antimicrobial profiles extracts of the leaves from Trichilia emetica Vahl. 
(Meliaceae)KK. Asian Pacific Journal of Tropical Biomedicine.2015; 
5(3): 242-248.
119. Brigitte KML, Flaurant TT, Emmanuel T. Antimicrobial, 
Antioxidant and Protective Effect of Methanol Extract of Trichilia 
emetica (Meliaceae) Stem and Root Bark against Free Radical-induced 
Oxidative Haemolysis. EJMP [Internet].2017; 19(1): 1-4.
120. Maroyi A. Zanha africana (Radlk.) Exell: review of its botany, 
medicinal uses and biological activities. Pharm. Sci. & Res.2019; 11(8): 
2980-2985.
121. Bode AM, Dong Z. Chapter 7. The Amazing and Mighty Ginger. 
In: Benzie IFF, Wachtel-Galor S, eds. Herbal Medicine: Biomolecular 
and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press/Taylor 
& Francis; 2011. Available from: https://www.ncbi. 
122. Chang JS, Wang KC, FengYeh CF, Shieh DE, Chiang LC. Fresh 
ginger (Zingiber officinale) has anti-viral activity against human 
respiratory syncytial virus in human respiratory tract cell lines. Journal 
of Ethnopharmacology. 2013;  145(1): 146-151.
123. Koh EM, Kim HJ, Kim S, eds. et al. Modulation of macrophage 
functions by compounds isolated from Zingiber officinale. Planta Med. 
2009; 75(2): 148-51.
124. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory 
syndrome coronavirus (MERS-CoV): announcement of the Coronavirus 
Study Group. J Virol. 2013; 87(14): 7790-7792.
Malawi Medical Journal 33 (2); 85-107 June 2021 Medicinal plants in Covid-19 disease management  93
https://dx.doi.org/10.4314/mmj.v33i2.4
Table 1: List of Medicinal Plants that were included in the study
1 
 









Adenia gummifera (Harv.) Harms 
Aeschynomene abyssinica 
Aframomum angustifolia 
Afzelia quanzensis Welw.  
Ageratum houstonia (compsitae) 
Albizia harveyi 
Albuca abyssinica Jacq. 
Algae spp. 
Allium sativum  




Ampelocissus obtusata (Welw. ex 
Baker) Planch. 












Boophone disticha (L.f.) 
Borassus aethiopum 
Boscia salicifolia Oliv 
Brachystegia allenii Hutch. & 
Burtt Davy 
Breonadia microcephala (Del.) 
Bridelia cathartica G. Bertol. 
Byrsocarpus orientalis (Baill.) 
Bak.  
Calotropis procera 
Canthium glaucum ssp.  
Carica papaya 
Cassia abbreviata 
Cassipourea mollis  
Cassytha filiformis L. 
Catunaregam spinosa 





Cissus rubiginosa (Welw.ex 
Baker) Planch 
Cissus sp. 











Crinum macowanii Baker 
Crossopteryx febrifuga 
Cryptolepis obtusa 
Cucumis hirsutus Sond. 
Cyphostema ssp. 
Cyphostemma junceum 
(Webb) Desc. ex Wild 








Dioscorea bulbifera L. 
Dioscorea dumetorum (Kunth) Pax 
Dioscorea esculenta (Lour.) 
Burkill 
Dioscorea odoratissima Pax 












Ekebergia benguelensis Welw. ex 
Elephantorrhiza goetzei 
Elytaria lyrata 
Eminia antennulifera (Baker) Taub 




Ficus capensis Thunb. 
Ficus kirkii Hutch. 
Ficus natalensis 
Ficus sycomorus 
Flacourtia indica  
Frueggea virosa 
Gladiolus dalenii Van Geel 








Hibiscus cannabinu L. 
Hippocratea parviflora 
Holarrhena pubescens 
Hymenocardia acida Tul. 
Hymenodictyon floribundum 
Hymenodictyon parvifolium 






Kaempferia rosea Schweinf. ex 
Baker 








Ledebouria cordifolia (Baker) 
Stedje & Thulin 





Manihot glaziovii Müll. Arg. 




Maytenus heterophylla or 
Gymnosporia buxifolia 
Maytenus senegalensis or G. 
senegalensis 
Melia azedarach 





Mucuna poggei Taub. 
Multidentia crassa 
Musa paradisiaca L. 
Neorautanenia mitis (A.Rich.) 
Verdc. 
Nidorella auricalata 
Nymphaea caerulea Savigny 
Terminalia kaiseriana 
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Table 2: List of Medicinal Plants that were evaluated further for Pharmacological and Physicochemical Properties
1 
 









Ageratum houstonia (compsitae) 
Albizia zimmermanii 
Albuca abyssinica Jacq. 
Algae spp. 




Ampelocissus Africana (Lour.) Merr. 

















Cissus rubiginosa (Welw.ex Baker) Planch. 








Cyphostemma junceum (Webb) 
Dalbergia nyassae, Swartzia madagascariensis 
Dicoma anomala Sond. 
Dicoma kirkii 
Dioscorea bulbifera L. 
Diplorhynchus condylocarpon 
Dolichos kilimandscharicus 
Dolichos trinervatus Baker 
Ectadiopsis oblongifolia 









Flueggea virosa, Securinega virosa 





Hypoxis villosa L.f. 
Ipomoea tenuirostris 
Jatropha curcas 






Momordica foetida Schumach & Thonn. 
Moringa oleifera 
Mucuna poggei Taub. 
Multidentia crassa 
Musa paradisiaca 
Neorautanenia mitis (A.Rich.) Verdc. 
Nidorella auricalata 
Oldfieldia dactylophylla  
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Table 3: Number of plants found to be used for each of the COVID-19 related diseases or symptoms
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Table 4: Medicinal plants used on more than one COVID-19 related disease
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Table 5: Literature Reported Pharmacological properties of medicinal plants with potential for use in COVID-19 disease
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